

Antibiotic-Inducible Promoter Regulated by the Cell Envelope Stress-Sensing Two-Component System LiaRS of *Bacillus subtilis*

Thorsten Mascher,[†] Sara L. Zimmer,[‡] Terry-Ann Smith,[‡]
and John D. Helmann^{*}

Department of Microbiology, Cornell University, Ithaca, New York 14853

Received 8 December 2003/Returned for modification 27 February 2004/Accepted 3 April 2004

Soil bacteria are among the most prodigious producers of antibiotics. The *Bacillus subtilis* LiaRS (formerly YvqCE) two-component system is one of several antibiotic-sensing systems that coordinate the genetic response to cell wall-active antibiotics. Upon the addition of vancomycin or bacitracin, LiaRS autoregulates the *liaIHGFSR* operon. We have characterized the promoter of the *lia* operon and defined the *cis*-acting sequences necessary for antibiotic-inducible gene expression. A survey for compounds that act as inducers of the *lia* promoter revealed that it responds strongly to a subset of cell wall-active antibiotics that interfere with the lipid II cycle in the cytoplasmic membrane (bacitracin, nisin, ramoplanin, and vancomycin). Chemicals that perturb the cytoplasmic membrane, such as organic solvents, are also weak inducers. Thus, the reporter derived from P_{liaI} (the *liaI* promoter) provides a tool for the detection and classification of antimicrobial compounds.

Soil bacteria inhabit a complex and highly variable environment. *Bacillus subtilis*, a ubiquitously distributed, low G+C gram-positive soil organism, is metabolically versatile and displays sophisticated regulatory responses that allow adaptation to changing environmental conditions (18). *Streptomyces coelicolor*, the model organism for the actinomycete family, has even greater genomic and regulatory complexity (4, 14). Bacteria from these groups produce large numbers of antibiotics, presumably as a mechanism to suppress the growth of competitors. The ability of these organisms to sense, and respond appropriately to, the presence of antibiotics is crucial to their survival.

We have used DNA microarray analyses to define the genetic responses of *B. subtilis* to two antibiotics present in its natural habitat, vancomycin and bacitracin (7, 22). The glycopeptide antibiotic vancomycin is produced by *Streptomyces toyocaensis* and other actinomycetes and binds tightly to D-Ala-D-Ala termini on the pentapeptide side chains of cell wall precursors, thereby inhibiting the formation of peptide cross-bridges by peptidyltransferase (34). While self-resistance of the producing strain has been reported (21), no vancomycin resistance mechanism has so far been described for *B. subtilis*. The branched cyclic dodecylpeptide antibiotic bacitracin is synthesized by *Bacillus licheniformis* and some strains of *B. subtilis* (2, 15). Bacitracin forms a tight complex with the undecaprenyl-pyrophosphate carrier that is released and recycled after the transglycosylation step of peptidoglycan biosynthesis. The presence of this antibiotic is sensed by a specific two-component system (BacRS in *B. licheniformis* and BceRS in *B. sub-*

tilis), which in turn strongly induces the expression of a bacitracin-specific ABC transporter that contributes to resistance (22, 25, 26). In other bacteria, reported resistance mechanisms involve the de novo synthesis of undecaprenol-pyrophosphate (6, 8), the target of bacitracin, and exopolysaccharide biosynthesis (27, 31).

Treatment of *B. subtilis* with sublethal concentrations of vancomycin or bacitracin induces overlapping regulons controlled by alternative sigma factors and two-component systems. Some regulons respond to a very small number of inducers (e.g., BceRS), whereas others (e.g., σ^M and LiaRS) respond to a variety of agents that perturb cell envelope functions (22). The histidine kinases of the three bacitracin-responsive two-component systems (LiaS, BceS, and YvcQ) share an unusually short sensing domain that is almost completely buried in the cytoplasmic membrane. This led us to hypothesize that they sense perturbations of cell envelope biosynthesis directly through the lipid interface. Therefore, these proteins were named intramembrane-sensing histidine kinases (22). The genes most strongly induced by both antibiotics were *liaIH* (formerly *yvqIH*), showing up to 1,000-fold increased induction in the expression level at 5 to 10 min after the addition of bacitracin. This induction was mediated by the response regulator LiaR. The genes for the corresponding two-component system, *liaSR*, are located directly downstream of the cotranscribed *liaIHGF* genes (22).

Here we characterize the LiaR-dependent, antibiotic-responsive promoter of the *liaIHGFSR* locus in *B. subtilis*. Of all antibiotics tested, this promoter is induced only by bacitracin, nisin, ramoplanin, and vancomycin, i.e., by antibiotics that interfere with the essential undecaprenol cycle in the cytoplasmic membrane. Based on the observed spectrum of its inducers, we renamed the YvqCE two-component system LiaRS (for lipid II cycle interfering antibiotic response regulator and sensor) and the remaining genes of this operon *liaIHGF*. We demonstrate that the P_{liaI} (*liaI* promoter) reporter system has potential as a

^{*} Corresponding author. Mailing address: Department of Microbiology, Wing Hall, Cornell University, Ithaca, NY 14853-8101. Phone: (607) 255-6570. Fax: (607) 255-3904. E-mail: jdh9@cornell.edu.

[‡] S.L.Z. and T.-A.S. contributed equally to this work.

[†] Present address: Abteilung für Allgemeine Mikrobiologie, Institut für Mikrobiologie und Genetik, Georg-August-Universität, D-37077 Göttingen, Germany.

TABLE 1. Strains, plasmids, and oligonucleotides used in this study

Strain, plasmid, or oligonucleotide	Characteristics or description	Reference or source
Strains		
<i>E. coli</i> DH5 α	ϕ 80 <i>lacZ</i> Δ m15 <i>recA1 endA1 gyrA96 thi-1 hsdR17</i> (r_{K}^{-} , m_{K}^{+}) <i>supE44 relA1 deoR</i> Δ (<i>lacZYA-argF</i>)U169	Laboratory stock
<i>B. subtilis</i>		
CU1065	W168 <i>attSPβ trpC2</i>	Laboratory stock
ZB307A	W168 SP β 2 Δ 2::Tn917::pSK10 Δ 6	37
BSF2469	CU1065 <i>liaH</i> ::pMUTIN	Zoltan Pragai
BSF2470	CU1065 <i>liaI</i> ::pMUTIN	Zoltan Pragai
HB0933	CU1065 <i>liaR</i> :: <i>kan</i>	22
HB0940	W168 SP β 2 Δ 2::Tn917:: Φ (<i>P</i> _{<i>liaI-29</i>} - <i>cat-lacZ</i>)	This work
HB0941	W168 SP β 2 Δ 2::Tn917:: Φ (<i>P</i> _{<i>liaI-58</i>} - <i>cat-lacZ</i>)	This work
HB0942	W168 SP β 2 Δ 2::Tn917:: Φ (<i>P</i> _{<i>liaI-74</i>} - <i>cat-lacZ</i>)	This work
HB0943	W168 SP β 2 Δ 2::Tn917:: Φ (<i>P</i> _{<i>liaI-83</i>} - <i>cat-lacZ</i>)	This work
HB0944	W168 SP β 2 Δ 2::Tn917:: Φ (<i>P</i> _{<i>liaI-193</i>} - <i>cat-lacZ</i>)	This work
HB0949	CU1065 SP β 2 Δ 2::Tn917:: Φ (<i>P</i> _{<i>liaI-58</i>} - <i>cat-lacZ</i>)	This work
HB0950	CU1065 SP β 2 Δ 2::Tn917:: Φ (<i>P</i> _{<i>liaI-74</i>} - <i>cat-lacZ</i>)	This work
HB0952	CU1065 SP β 2 Δ 2::Tn917:: Φ (<i>P</i> _{<i>liaI-58</i>} - <i>cat-lacZ</i>), <i>liaR</i> :: <i>kan</i>	This work
HB0953	CU1065 SP β 2 Δ 2::Tn917:: Φ (<i>P</i> _{<i>liaI-74</i>} - <i>cat-lacZ</i>), <i>liaR</i> :: <i>kan</i>	This work
Plasmids		
pJPM122	<i>cat-lacZ</i> operon fusion vector for SP β	30
pSLZ29	pJPM122 with <i>P</i> _{<i>liaI-29</i>}	This work
pSLZ58	pJPM122 with <i>P</i> _{<i>liaI-58</i>}	This work
pSLZ74	pJPM122 with <i>P</i> _{<i>liaI-74</i>}	This work
pSLZ83	pJPM122 with <i>P</i> _{<i>liaI-83</i>}	This work
pSLZ193	pJPM122 with <i>P</i> _{<i>liaI-193</i>}	This work
Oligonucleotides^a		
1312	yyqH fwd: GGAGGAATCAGGTATGG	
1314	yyqH rev: CTTGACCGCAAATCCTTCC	
1779	yyqG fwd: CAACTCTTATCGTCAGGCTTCCG	
1311	yyqH-do rev: CGCTAGATCCCCGCTGTCC	
1503	PyvqI-559: GGATCTGCAGGGTTTGTGCTGGCGAAAGTCAAGG	
1628	yyqI-PE: TTAATAAGAATCCGCCTATTG	
1310	yyqH-do fwd: GCAGACCAGACAAAAGCGGC	
1629	yyqG-PE: TCCGCTATAATCCGGACATCC	
1506	PyvqI-193: CCATCTGCAGGCCAAAAGCAGAAAGGTCCGACC	
1507	PyvqI-83: CCATCTGCAGCCGGTGCAGATACGACTCC	
1508	PyvqI-74: GGATCTGCAGGATACGACTCCGGTCTTATATAAAAAATC	
1509	PyvqI-58: GGATCTGCAGTATATAAAAAATCAATCTCTGATTCCG	
1510	PyvqI-29: GGATCTGCAGGCATATCTTCCAACCTTG	
1511	PyvqI+93: CGATGGATCCTCCTCCAAAAAAGACGGAGATCCC	

^a Numbers and names of the oligonucleotides are according to the Helmann laboratory oligonucleotide collection. Restriction sites are underlined.

screening tool for antibiotics: it shows a very sensitive, concentration-dependent response to its identified inducers.

MATERIALS AND METHODS

Media and growth conditions. *B. subtilis* and *Escherichia coli* were routinely grown in Luria broth medium at 37°C with aeration. Ampicillin (100 μ g/ml) was used for selection of plasmid pJPM122 and its derivatives in *E. coli*. Kanamycin (100 μ g/ml), neomycin (10 μ g/ml), chloramphenicol (1 μ g/ml), and erythromycin (1 μ g/ml) plus lincomycin (25 μ g/ml) for macrolide-lincosamide-streptogramin resistance, were used for the selection of the *B. subtilis* mutants used in this study.

Bacterial strains and plasmids. The strains of *E. coli* and *B. subtilis*, as well as the plasmids used, are listed in Table 1. SP β phages are derivatives of SP β c2 Δ 2 and were constructed by the integration of a promoter region-*cat-lacZ* fusion constructed in plasmid pJPM122 into *B. subtilis* strain ZB307A as described previously (30). SP β lysates were prepared by heat induction from the lysogenic strains as described (37).

DNA manipulations and sequencing. The preparation of chromosomal DNA, transformation, and SP β transduction were performed according to standard procedures (9). *E. coli* plasmid DNA and restriction enzyme fragments were isolated by using the QIAprep spin miniprep and PCR purification kits, respectively (QIAGEN Inc., Chatsworth, Calif.). Restriction endonucleases, DNA li-

gase (New England Biolabs, Beverly, Mass.), *Pfu* DNA polymerase (Stratagene, La Jolla, Calif.), and HotStar DNA polymerase (QIAGEN Inc.) were used according to manufacturers' instructions. DNA sequencing was performed with AmpliTaq-FS DNA polymerase and dye terminator chemistry by the DNA services facility of the Cornell New York State Center for Advanced Technology-Biotechnology.

Northern analysis of *liaH* and *liaG*. Total RNA was extracted from 5 ml of *B. subtilis* CU1065 culture with and without bacitracin (final concentration, 10 μ g/ml). Bacitracin was added to the culture at an optical density at 600 nm (OD_{600}) of 0.45 (mid-log phase), and the cultures were incubated for 15 min at 37°C with aeration before the cells were harvested and rapidly frozen at -80°C. RNA was prepared by using the RNeasy kit (QIAGEN) according to the manufacturer's protocol. Internal fragments of *liaH* and *liaG* (500- to 750-nucleotide length) were amplified by PCR by using the primer pairs 5' 1312-3' 1314 and 5' 1779-3' 1311 (Table 1). The PCR fragments were purified by using the QIAGEN PCR purification kit, and 100 ng of each fragment was labeled with [α -³²P]dATP (3,000 Ci/mmol, 10 mCi/ μ l; New England Nuclear) by random oligonucleotide-primed synthesis with the Klenow fragment of DNA polymerase (3'→5' exo⁻; New England Biolabs) according to a published procedure (3.5.9-10) (1). Unincorporated [α -³²P]dATP was removed by NucAway spin columns (Ambion).

Northern analysis was carried out by using the NorthernMax formaldehyde-based system (Ambion) according to the manufacturer's instruction, with 10 μ g

of total RNA and Zeta-Probe blotting membrane (Bio-Rad) in a downward transfer setup. After hybridization and washing of the membranes, the blots were wrapped in plastic wrap, exposed for 12 h to a phosphor screen (Molecular Dynamics) and analyzed by a PhosphorImager (Molecular Dynamics).

Primer extension mapping of the *liaI* promoter site. For mapping of the *liaI* promoter, *B. subtilis* CU1065 cells were grown in LB, and total RNA was isolated from uninduced and bacitracin-induced (final concentration, 10 μ g/ml) mid-log phase cultures as described above. Primer extension reactions for *liaI* were set up as follows: 30 μ g of heat-denatured RNA was hybridized at 65°C to ~2 pmol of end-labeled primer 1628 in buffer containing 60 mM NaCl, 50 mM Tris-HCl (pH 7.9), 10 mM dithiothreitol (DTT), and 40 U of RNasin (Promega) in a total volume of 30 μ l. Following hybridization, 50 μ l of extension buffer (72 mM NaCl, 50 mM Tris-HCl [pH 7.9], 10 mM DTT, 20 mM MgCl₂), 10 mM concentrations of the deoxynucleoside triphosphates, and 2 μ l of Superscript II reverse transcriptase (Invitrogen, Carlsbad, Calif.) were added to the mixture, and incubation continued at 37°C for 30 min. The primer extension products were precipitated with ethanol, resuspended in sequence loading buffer, and loaded onto a 6% polyacrylamide sequencing gel. A PCR cycle sequencing kit (Epicentre, Madison, Wis.) was used to generate sequencing ladders corresponding to the *liaI* promoter region.

Construction of *cat-lacZ* reporter fusions for P_{liaI} dissection. For the P_{liaI} -*cat-lacZ* fusions, promoter fragments of increasing lengths were generated by PCR by using the 5' primer pair 1506-1510 with the 3' primer 1511 (Table 1). The PCR was performed in a total volume of 50 μ l with Pfu DNA polymerase (Stratagene, La Jolla, Calif.) according to the manufacturer's instruction. The reactions were initially denatured for 2 min at 94°C, followed by 30 cycles of 20 s at 94°C, 30 s at 50°C, 30 s at 72°C, and a final extension of 5 min at 72°C. The resulting PCR products were cloned into pJPM122 (30) as a PstI-to-BamHI fragment (Table 1; restriction sites are underlined in primer sequences), resulting in promoter-*cat-lacZ* fusions in plasmids pSLZ29 (as a negative control, lacking the -35 region of P_{liaI}), pSLZ58 (core promoter), pSLZ74 (single TC CGGT sequence included), pSLZ83 (complete TCCGGT repeat), and pSLZ193 (positive control) (see Fig. 2). The inserts were verified by DNA sequencing at the Cornell BioResource Center. The plasmids were linearized and used to transform ZB307A with neomycin selection to generate strains HB0940 to HB0944. Phages generated from strains HB0941 and HB0942 (SP β 0941 and SP β 0942, respectively) were used to transduce the P_{liaI} -*cat-lacZ* fusions into *B. subtilis* strains CU1065 and HB0933, resulting in strains HB0940/0950 and HB0952/0953, respectively (Table 1).

P_{liaI} induction assays. Screening for *liaI* induction was done by disk diffusion assay essentially as described (7). *B. subtilis* strains were inoculated from a fresh overnight LB agar plate and grown to mid-log phase (OD₆₀₀ of ~0.45) at 37°C with shaking. A total of 20 μ l of the culture was mixed with 3 ml of 0.7% soft LB agar (containing 40 μ g of XGal per plate) and poured onto the bottom agar. After cooling and drying of the plates (20 min at 37°C), filter paper disks (6-mm diameter) carrying 5 μ l of stock solution (antibiotics normally at a concentration of 100 mg/ml each; lysozyme at a concentration of 10 mg/ml; tunicamycin, surfactants, and uncouplers at a concentration of 5 mg/ml each; inhibitors of protein biosynthesis as given in "Media and growth conditions") were placed on top of the agar. The plates were incubated at 37°C overnight. After incubation for 12 to 24 h, the plates were scored for the appearance of blue rings at or near the edge of the zones of growth inhibition produced by the diffusion of the antibiotics from the filter disks.

For quantitative measurements of β -galactosidase activity, cells were inoculated from fresh overnight LB plates and grown in LB medium at 37°C with aeration until they reached an OD₆₀₀ of 0.45. A total of 2 ml of the culture was harvested (uninduced control), and the cell pellets were frozen and kept at -80°C. The cultures were induced by the addition of the compound to be tested to the final concentration as described in the individual figure legends and incubated for an additional 30 min at 37°C. Cultures (2-ml) were harvested as described above. The pellets were resuspended in 1 ml of working buffer (60 mM Na₂HPO₄, 40 mM NaH₂PO₄, 10 mM KCl, 1 mM MgSO₄, 0.4 mM DTT) and assayed for β -galactosidase activity as described with normalization to cell density (23). For concentration-dependent induction and killing experiments, cultures of strain BFS2470 were grown in LB medium to mid-log growth phase (OD₆₀₀ of 0.4 to 0.45), and the antibiotics were added to a final concentration ranging from 0.01 to 100 μ g/ml. An uninduced culture was used as a negative control. The cultures were incubated with aeration at 37°C. A sample was taken after 30 min for the β -galactosidase assay, and the turbidity of the remaining culture was measured for at least 5 h to monitor the concentration-dependent effects of the antibiotics on cell growth.




FIG. 1. Organization and bacitracin-dependent expression of the *liaIHGFSR* locus of *B. subtilis*. (a) Graphic representation of the *lia* locus including *liaS* (histidine kinase) and *liaR* (response regulator). The *psrA* homolog *liaH* is shown in black. Genes coding for proteins with unknown function are shown in gray; the genes flanking the *lia* locus are white. The line corresponds to a size of 7.5 kb. In the course of this work we noticed two errors in the original genome sequence in the noncoding region between *liaH* and *liaG*. The corrected sequence resulted in an addition of 150 nucleotides at the 5' end of *liaG*. The fragments used as probes for *liaH* and *liaG* in the Northern blot (panel b) are represented as thick black bars above the locus. (b) Northern blot showing the bacitracin-dependent expression of *liaH* and *liaG*. Expression of each gene was measured by using 10 μ g of total RNA from each sample separated on a 1% formaldehyde gel. RNA was transferred to a nylon membrane and hybridized with radiolabeled DNA fragments of the indicated genes. -, uninduced control lane; +, the RNA sample from cultures induced with bacitracin for 15 min (final concentration of 10 μ g/ml). The two transcripts are indicated with arrowheads, and the approximate sizes corresponding to *liaIH* (1.1 kb) and the whole *lia* locus (~4 kb) are given. The thin band between the transcripts represents an artifact derived from the quenching of the 4-kb transcript by the abundant 23S rRNA, which can saturate available binding sites on the hybridization membrane. (c) Secondary structure of the stem-loop directly downstream of *liaH*.

RESULTS

The *liaIHGFSR* locus forms an operon. The expression of the *liaIHGFSR* operon is very tightly regulated and completely LiaR dependent, as shown previously (22). Only a very faint transcript of 1.1 kb, corresponding to *liaIH*, can be detected by Northern analysis in uninduced mid-log phase cultures (Fig. 1b). Upon the addition of bacitracin, two transcripts are strongly induced, corresponding to *liaIH* and the complete *liaIHGFSR* locus (Fig. 1b). This expression pattern may result from transcription termination downstream of *liaH* (Fig. 1c). The presence of the LiaRS two-component system is a prerequisite for this strong induction.

Previous work on the bacitracin stimulon suggested an independent low-level expression of *liaGFSR* (22). To investi-

gate this further, Northern analysis was performed by using a *liaG*-specific probe. No transcript could be detected in uninduced cultures, and upon bacitracin induction only the full-length transcript appeared (Fig. 1b). Primer extension analysis also failed to detect a transcriptional start site upstream of *liaG* (data not shown). These results suggest that the *lia*-locus is expressed from the LiaR-dependent promoter upstream of *liaI* (Fig. 1b). Since LiaRS is required for antibiotic induction, we conclude that it must be expressed even in uninduced cells. Since the number of sensors needed for signal transduction is very low (~100 molecules of EnvZ per *E. coli* cell [5]), the lack of a detectable long transcript in uninduced mid-log phase cultures for the *lia* locus is not too surprising.

Identification of the minimal promoter for the *liaI* operon.

We mapped the transcriptional start site upstream of *liaI* by using primer extension analysis (Fig. 2). Transcription initiates at an A residue 25 nucleotides upstream of the *liaI* start codon. The *liaI* promoter shows a well-conserved -10 region (TAT AAG) and a weakly conserved -35 region (TTCGTT). Response regulators that act as transcriptional activators normally interact with DNA via short, 6- to 10-nucleotide binding sites in close proximity upstream of the promoter. These binding sites can either occur singly or as repeated elements with a spacing of about 8 to 10 nucleotides (16), allowing the response regulator dimer to bind in two neighboring major grooves of the DNA. In the 60 nucleotides between the -35 region and the putative terminator of *yvqJ*, we identified a 6-nucleotide direct repeat (TCCGGT) with a 12-nucleotide spacing as a candidate site for DNA binding by LiaR.

To analyze P_{liaI} and this putative binding site further, we used a *lacZ*-based promoter dissection approach. Fragments of P_{liaI} ending at position +97 (inside of *liaI*) and extending to different lengths upstream of the transcriptional start site (Fig. 2c) were used to generate reporter fusions integrated at SP β . All constructs had very low *lacZ*-expression in the uninduced state (Fig. 2d). The core promoter alone (-58) was not bacitracin inducible and showed only marginally higher expression than the negative control (extending to -29). However, the presence of 16 additional nucleotides (-74), including one copy of the TCCGGT sequence, allowed full induction upon the addition of bacitracin, as also seen with the two larger fragments (extending to -83 and -193). The minimal bacitracin-inducible promoter as defined by these studies is underlined in Fig. 2b. As expected, bacitracin-dependent induction was completely lost in the *liaR*-deletion mutant HB0953 (data not shown).

P_{liaI} is induced by antibiotics that interfere with the lipid II cycle. P_{liaI} is specifically induced by vancomycin and bacitracin, two antibiotics that interfere with the cycling of lipid II (22). To gain a better understanding of the sensing process, we expanded our analysis to define the range of inducers. Disk diffusion assays were used to screen a variety of antibiotics for the ability to induce β -galactosidase expression from a chromosomal pMUTIN-based *liaI'*-*lacZ* fusion in strain BSF2470 (Table 2). The use of pMUTIN leads to an insertion-duplication disruption of a targeted gene, while at the same time putting *lacZ* under the control of the promoter region of the disrupted gene (33). In addition to the previously identified inducers (bacitracin and vancomycin), the cell wall antibiotics tunicamycin, ramoplanin, nisin, and (weakly) fosfomycin gave

a blue ring at the edge of the zone of inhibition, indicating an induction of *liaI* expression at sublethal concentrations. Negative results were observed for other antibiotics including chloramphenicol, kanamycin, rifampin, spectinomycin, streptomycin, and tetracycline (data not shown).

In quantitative β -galactosidase assays, performed on cells growing in liquid cultures, both nisin and ramoplanin were strong inducers (420-fold increase in induction), as were bacitracin (500-fold increase) and vancomycin (63-fold increase), consistent with earlier studies (22) (Table 2). Equivalent levels of induction were also observed with the $P_{liaI-74}$ -*cat-lacZ* fragment (in HB0950), albeit with smaller increases (Table 2). While the mode of action is different for these antibiotics, all four interfere with the lipid II cycle that is essential for the biosynthesis of cell envelope polymers (20). Tunicamycin and fosfomycin were weak inducers in the liquid assays (Table 2).

To analyze the specificity of the P_{liaI} -*lacZ* system further, we tested several detergents and surfactants. Detergents like sodium dodecyl sulfate (SDS) and Triton X-100 compromise the integrity of the cytoplasmic membrane. Surfactants serve as emulsifiers by adsorbing and altering the conditions at interfaces due to their amphiphatic nature (24). Detergents did not induce *liaI* expression in the zone of the inhibition assay and were not further analyzed. Of the three surfactants chosen for our analysis, only benzyltrimethylhexadodecylammonium chloride (BDMHDA-Cl) moderately induced *liaI* expression (Table 2). Organic solvents such as diphenyl ether, *n*-hexane, and cyclooctane also led to an 8- to 12-fold increase in induction. Organic solvents are toxic because they nonspecifically accumulate in and disrupt the cytoplasmic membrane (29).

The *liaI* and *liaH* genes code for a small, presumably membrane-bound, protein and a homolog of *E. coli* *pspA* (phage-shock protein A), respectively. PspA is involved in the maintenance of cell membrane integrity and proton motive force and is induced by uncouplers such as carbonyl cyanide *m*-chlorophenylhydrazone and dinitrophenol (36). Although we included these two uncouplers in our screening, neither elevated the level of *liaIH* expression (data not shown). Lysozyme, which breaks the glycosidic bounds between *N*-acetylmuramic acid and *N*-acetylglucosamine in peptidoglycan, was also ineffective as an inducer (data not shown).

Concentration-dependent induction and killing experiments were performed for bacitracin, nisin, ramoplanin, and vancomycin. In all four cases the induction of *liaI* occurred in a concentration-dependent manner (Fig. 3a), reaching a maximum at an antibiotic concentration of about 10 μ g/ml (1 μ g/ml for vancomycin). While the level of *lacZ* expression remained elevated at higher concentrations of bacitracin and vancomycin, a strong decrease down to uninduced levels was observed for nisin and ramoplanin. This finding correlates well with the bactericidal effects of these antibiotics as inferred from the dramatic decrease in optical density: there is little effect from bacitracin and vancomycin on cell growth during the first 30 to 60 min after the addition of the antibiotics even at high concentrations (Fig. 3b). In contrast, high concentrations of nisin and ramoplanin led to rapid cell lysis, which likely interfered with the induction of β -galactosidase (Fig. 3b).






TABLE 2. Inducers of *liaI* expression

Inducer ^a	Disk diffusion assay ^b	Concn (μg/ml) ^c	Increase (<i>n</i> -fold) in induction ± SD ^d	
			BFS2470	HB0950
Cell wall antibiotics				
Ampicillin	–			
Bacitracin	+	10	498 ± 92	192 ± 16
Cephalosporin	–			
D-cycloserin	–			
Fosfomycin	(+)	10	1.7 ± 0.6	
Moenomycin	–			
Nisin	+	10	423 ± 16	156 ± 8.3
Penicillin G	–			
Polymyxin B	–			
Ramoplanin	+	5	422 ± 60	144 ± 12
Tunicamycin	+	50	3.1 ± 1.1	
Vancomycin	+	2	63 ± 2.7	36 ± 0.2
Organic solvents				
Diphenyl ether	NT	10	10.8 ± 3.4	
<i>n</i> -Hexane	NT	10	7.8 ± 1.2	
Cyclooctane	NT	10	11.6 ± 4.9	
Surfactants ^e				
BDMDDA-Br	–			
BDMHDA-Cl	+	10	8.2 ± 1.9	
HDTMA-Br	–			

^a Strong inducers are in bold.

^b Qualitative screen of β-galactosidase activity in strain BFS2470; activity was assessed by the appearance of a blue ring around the edge of the zone of inhibition on LB plates supplemented with X-Gal. –, no induction; +, induction of *liaI* expression; (+), very weak induction in disk diffusion assays; NT, not tested.

^c The concentration resulting in the highest level of induction was used.

^d Quantitative β-galactosidase assay in liquid with the pMUTIN-derived (strain BFS2470; Table 1) and pJPM122-derived minimal promoter system (strain HB0950; Table 1). Cells were cultured in LB medium to mid-log phase and induced by the addition of the drug to be tested to the final concentration given. Cells were harvested and the assay was performed as described in Materials and Methods. Results are expressed as the increase relative to uninduced control. The background activity for the uninduced samples was about 3 to 5 (strain BFS2470) and 0.5 (strain HB0950) Miller units.

^e BDMDDA-Br, benzyltrimethylhexadecylammonium bromide; BDMHDA-Cl, benzyltrimethylhexadecylammonium chloride; HDTMA-Br, hexadecyltrimethylammonium bromide.

DISCUSSION

The emergence of antibiotic-resistant pathogens only a few decades after the first clinical use of antibiotics has revived the search for novel antibacterial compounds. The two most common strategies for the identification of new lead compounds involve either target-based approaches or whole-cell screening for bactericidal compounds (28). Target-based approaches focus on essential, conserved genes that are limited to the bac-

terial world (11). Whole-cell approaches often begin with the high-throughput screening of high-complexity natural product or synthetic chemical libraries. In each case, active compounds must be carefully analyzed to infer the mechanisms of action and to assess toxicity. The prerequisites for efficient screening are unchanged and challenging: assays need to be robust, specific, and sensitive (35). Transcriptional profiling has emerged as a useful tool to identify promoters that respond to specific antibiotic stresses and thereby aid in the functional classification of active compounds (13).

The *liaIH* (formerly *yvqIH*) genes are strongly induced in the presence of cell wall antibiotics such as vancomycin and bacitracin (22). This induction depends on the activity of the LiaRS two-component system (formerly YvqCE) (22). In this report we analyzed the regulation and expression of the *liaIHGFSR* operon in detail. This operon is transcribed from a single LiaR-dependent, σ^A-type promoter upstream of *liaI*, and a minimal promoter extending to position –74 relative to the transcription start point was fully inducible (Fig. 2a to c). A stem-loop sequence between *liaH* and *liaG* is correlated with the appearance of two different transcripts: a short 1.1-kb large RNA covering *liaIH* and a long transcript, including the whole locus (Fig. 1). The higher abundance of *liaIH* relative to *liaGFSR* mRNA may be due to termination at this stem-loop structure or to stabilization of the smaller transcript against degradation. No terminator structure could be detected downstream of *liaR*, and its 3' end is only separated by eight nucleotides from the 3' end of the convergently transcribed *gerAC* gene.

The P_{*liaI*} system described here has several features that recommend it as a useful tool for the detection and classification of compounds eliciting cell envelope stress. Like the VanRS system (32), which is already used in high-throughput screening, the minimal P_{*liaI*} promoter can be used to construct quantifiable reporter fusions such as the *lacZ* fusion reported here. The P_{*liaI*}-*lacZ* reporter fusion has very low basal levels of expression, responds in a concentration-dependent manner to antibiotics, and reaches high levels of induction (Table 2 and Fig. 3a). The dynamic range of P_{*liaI*} is very high (up to 400-fold increased specific induction compared to a 5- to 10-fold increase reported for VanRS-based reporters in *B. subtilis* [32]), which suggests that LiaRS-based systems may allow for the sensitive detection of lipid II cycle-interfering antibiotics (Table 2) and discrimination against compounds that nonspecifically perturb the cytoplasmic membrane. In contrast, the VanRS system (32) is induced by a broader range of cell wall

FIG. 2. Functional dissection of the *liaI* promoter P_{*liaI*}. (a) Primer extension mapping of the *liaI* transcriptional start site indicates transcription initiation with the A residue indicated in the sequence to the right. (b) Intergenic sequence between *yvqJ* and *liaI*. All features are marked underneath the respective lines of the sequence. The end of *yvqJ* and the beginning of *liaI* are labeled. The putative *yvqJ* terminator is indicated by the black arrows. The expression signals for *liaI* are labeled (–35 and –10 for the promoter and RBS for the putative ribosome binding site). A direct repeat sequence is boxed (see text). The 5' ends of the fragments used for the promoter dissection are marked and labeled according to their positions relative to the transcriptional start site (see below). The minimal bacitracin-inducible promoter fragment, based on the promoter dissection, is underlined. (c) Graphical representation of the intergenic region and outline of the fragments used for the promoter dissection. The features of the region are represented by black boxes and labeled as above. The arrow indicates the transcriptional start site. term, terminator. (d) β-Galactosidase assay for promoter dissection. Cultures of the P_{*liaI*} reporter strains HB0940 (–29), HB0941 (–58), HB0942 (–74), HB0943 (–83), and HB0944 (–193) were grown to mid-log phase (OD₆₀₀ of ~0.45) and induced by the addition of bacitracin (final concentration, 10 μg/ml). Cells were harvested 30 min postinduction and assayed as described in Materials and Methods. β-Galactosidase activity, plotted on a logarithmic scale for clarity, is expressed in Miller units (23). Dark gray bars represent the induced sample, and light gray bars indicate the uninduced control sample for each strain. Each experiment was performed at least twice, and the standard deviations are indicated by error bars.




FIG. 3. Concentration-dependent induction of *liaI* and optical density changes for *B. subtilis* cultures treated with bacitracin, nisin, ramoplanin, and vancomycin. (a) β -Galactosidase assays were performed as described in the legend of Fig. 2. by using strain BFS2470 and different concentrations of the four antibiotics as indicated. Miller units are plotted on a logarithmic scale for clarity. (b) Concentration-dependent killing of *B. subtilis* by the four antibiotics from the same culture as described in panel a. The times of antibiotic addition are indicated by arrows. The concentrations of bacitracin (□, 50; ◇, 100; and ○, 500 μ g/ml), nisin (□, 50; ◇, 70; and ○, 100 μ g/ml), ramoplanin (□, 20; ◇, 50; and ○, 100 μ g/ml), and vancomycin (□, 5; ◇, 10; ○, 50; and △, 100 μ g/ml) that affect the induction of P_{liaI} according to the β -galactosidase assay are indicated.

antibiotics (S. Donadio, personal communication). The P_{liaI} reporter assay could be further simplified by using the *lux* reporter (luciferase) instead of *lacZ*. The *lux* operon of *Photobacterium luminescens* has been adapted and optimized for use in gram-positive bacteria (12). This system does not need an exogenous substrate and produces high levels of light at 37°C, the optimal growth temperature for *B. subtilis*. It has already been used successfully in *Staphylococcus aureus*, *Streptococcus pneumoniae*, and *Listeria monocytogenes* (12).

We tested a wide range of antibiotics and cell envelope-damaging substances for their ability to induce *liaIH* gene expression. Based on the nature and strength of the transcriptional response, three groups of inducers can be defined. The strongest inducers (bacitracin, nisin, ramoplanin, and vancomycin) result in a 63- to 400-fold increase in induction of *liaIH* expression. Indeed, upon induction LiaH is sufficiently abundant to be easily detected in two-dimensional gel electrophoresis and has been assigned as a signature protein for bacitracin-treated cells (3). All four of these antibiotics directly interfere with the essential lipid carrier of cell envelope biosynthesis (see below). The second group consists of weak inducers including some organic solvents and one surfactant (BDMHDA-Cl). Organic solvents accumulate in the hydrophobic interior of the cytoplasmic membrane and may indirectly affect the lipid II cycle. Alternatively, they could interfere with the proposed intramembrane-sensing domain of LiaS (see below). Two of the three surfactants and the two detergents (SDS and Triton X-100) that were tested failed to induce *liaIH* expression, at least in the plate-based assay. All of these compounds are strong inducers for the VanRS two-component system (32), for which BDMHDA-Cl induces at a concentration 50-fold lower than SDS (S. Donadio, personal communication). We therefore conclude that some as yet unknown properties of BDMHDA-Cl account for the 10-fold increase in induction of *liaIH* expression. The third group includes some cell wall-active antibiotics that appear to elicit transcriptional induction on plates but for which very weak activity is seen in liquid cultures (Table 2).

Undecaprenol serves as the lipid carrier for cell envelope building blocks which are covalently linked through a phosphoryl group on the cytoplasmic side of the membrane. Once transferred to the extracytoplasmic side of the membrane, lipid II donates the disaccharide-pentapeptide units into the growing peptidoglycan network. Undecaprenol is an essential molecule, and its recycling is a rate-limiting step in cell envelope growth (10). The lipid II cycle is, therefore, an ideal target for antibiotic action. The cell's ability to monitor the state of this crucial process can be viewed as a regulatory device to ensure normal growth and to rapidly detect and respond to perturbations that might result in cell death. The ability of LiaS to sense perturbations of the lipid II cycle is in good agreement with our hypothesis that LiaS, a member of the proposed subfamily of intramembrane-sensing histidine kinases, detects its signal at the membrane interface (22). The LiaRS two-component system may thereby sense a whole group of harmful substances through their effect on a common cellular process.

The importance of this antibiotic-sensing two-component system is stressed by the identification of homologous systems in other gram-positive bacteria. One homologous two-component system, VraSR from *S. aureus*, is induced by bacitracin

and vancomycin and also by other cell wall antibiotics, such as D-cycloserine, imipenem, and ceftizoxime (19). It controls a large regulon, with some target genes having predicted functions linked to cell wall metabolism. Consequently, a VraSR deletion strain shows a significant increase in sensitivity to the antibiotics it senses (19). In contrast, deletion of LiaR target genes does not result in antibiotic sensitivity (22). We suggest that LiaRS and its homologs represent a group of two-component systems that sense damage to the cell envelope. The differences in the spectrum of cell wall antibiotics sensed by these two histidine kinases may be indicative of an evolutionary diversification or specialization within this group of cell wall stress sensors. We note that VraS from *S. aureus* and *Staphylococcus epidermidis* shows the maximum phylogenetic distance to LiaS inside the LiaS subgroup of intramembrane-sensing histidine kinases. This difference is especially pronounced in the transmembrane-sensing domain of the proteins (data not shown).

Our investigations so far have only focused on the *lia* locus itself. A comprehensive microarray analysis of two-component systems in *B. subtilis* mutants overexpressing the cognate response regulators identified additional putative target genes for LiaRS (17). While we were not able to reproduce all of these authors' findings, there are indications that LiaRS controls more than one target locus and is part of a regulatory cascade (22). An analysis of its regulon is currently under way and will serve as a starting point to identify LiaR-binding sites. The tight regulation and very strong induction of *liaIH* suggest an important biological function for its gene products, which will be a focus for further studies.

ACKNOWLEDGMENTS

We thank S. Donadio (Vicuron) for the generous gift of purified ramoplanin, P. Welzel for the purified moenomycin, and Z. Pragai for the gift of strains BFS2469 and BFS2470. We also thank A. Goldborough (RNAworks) for information on quenching of signals by rRNA and S. Donadio for helpful discussions and critical reading of the manuscript.

This work was supported by NIH grant GM-47446 (to J.D.H.).

REFERENCES

1. Ausubel, F. M., R. Brent, K. R. E., D. D. Moore, J. G. Seidman, J. A. Smith, and S. K. (ed.). 2003. Current protocols in molecular biology. John Wiley & Sons, New York, N.Y.
2. Azevedo, E. C., E. M. Rios, K. Fukushima, and G. M. Campos-Takaki. 1993. Bacitracin production by a new strain of *Bacillus subtilis*. Extraction, purification, and characterization. *Appl. Biochem. Biotechnol.* **42**:1-7.
3. Bandow, J. E., H. Brotz, L. I. Leichert, H. Labischinski, and M. Hecker. 2003. Proteomic approach to understanding antibiotic action. *Antimicrob. Agents Chemother.* **47**:948-955.
4. Bentley, S. D., K. F. Chater, A. M. Cerdeno-Tarraga, G. L. Challis, N. R. Thomson, K. D. James, D. E. Harris, M. A. Quail, H. Kieser, D. Harper, A. Bateman, S. Brown, G. Chandra, C. W. Chen, M. Collins, A. Cronin, A. Fraser, A. Goble, J. Hidalgo, T. Hornsby, S. Howarth, C. H. Huang, T. Kieser, L. Larke, L. Murphy, K. Oliver, S. O'Neil, E. Rabinowitsch, M. A. Rajandream, K. Rutherford, S. Rutter, K. Seeger, D. Saunders, S. Sharp, R. Squares, S. Squares, K. Taylor, T. Warren, A. Wietzorrek, J. Woodward, B. G. Barrell, J. Parkhill, and D. A. Hopwood. 2002. Complete genome sequence of the model actinomycete *Streptomyces coelicolor* A3(2). *Nature* **417**:141-147.
5. Cai, S. J., and M. Inouye. 2002. EnvZ-OmpR interaction and osmoregulation in *Escherichia coli*. *J. Biol. Chem.* **277**:24155-24161.
6. Cain, B. D., P. J. Norton, W. Eubanks, H. S. Nick, and C. M. Allen. 1993. Amplification of the *bacA* gene confers bacitracin resistance to *Escherichia coli*. *J. Bacteriol.* **175**:3784-3789.
7. Cao, M., T. Wang, R. Ye, and J. D. Helmann. 2002. Antibiotics that inhibit cell wall biosynthesis induce expression of the *Bacillus subtilis* σ^W and σ^M regulons. *Mol. Microbiol.* **45**:1267-1276.

8. Chalker, A. F., K. A. Ingraham, R. D. Lunsford, A. P. Bryant, J. Bryant, N. G. Wallis, J. P. Broskey, S. C. Pearson, and D. J. Holmes. 2000. The *bacA* gene, which determines bacitracin susceptibility in *Streptococcus pneumoniae* and *Staphylococcus aureus*, is also required for virulence. *Microbiology* **146**:1547–1553.
9. Cutting, S. M., and P. B. VanderHorn. 1990. Genetic analysis, p. 27–74. In C. R. Harwood and S. M. Cutting (ed.), *Molecular biological methods for discovering novel antibacterial agents*. J. Biotechnol. **99**:175–185.
10. Delcour, J., T. Ferain, M. Deghorain, E. Palumbo, and P. Hols. 1999. The biosynthesis and functionality of the cell-wall of lactic acid bacteria. *Antonie Leeuwenhoek* **76**:159–184.
11. Donadio, S., L. Carrano, L. Brandi, S. Serina, A. Soffientini, E. Raimondi, N. Montanini, M. Sosio, and C. O. Gualerzi. 2002. Targets and assays for discovering novel antibacterial agents. *J. Biotechnol.* **99**:175–185.
12. Francis, K. P., D. Joh, C. Bellinger-Kawahara, M. J. Hawkinson, T. F. Purchio, and P. R. Contag. 2000. Monitoring bioluminescent *Staphylococcus aureus* infections in living mice using a novel *luxABCDE* construct. *Infect. Immun.* **68**:3594–3600.
13. Hughes, D. 2003. Exploiting genomics, genetics and chemistry to combat antibiotic resistance. *Nat. Rev. Genet.* **4**:432–441.
14. Ikeda, H., J. Ishikawa, A. Hanamoto, M. Shinose, H. Kikuchi, T. Shiba, Y. Sakaki, M. Hattori, and S. Omura. 2003. Complete genome sequence and comparative analysis of the industrial microorganism *Streptomyces avermitilis*. *Nat. Biotechnol.* **21**:526–531.
15. Ishihara, H., M. Takoh, R. Nishibayashi, and A. Sato. 2002. Distribution and variation of bacitracin synthetase gene sequences in laboratory stock strains of *Bacillus licheniformis*. *Curr. Microbiol.* **45**:18–23.
16. Kenney, L. J. 2002. Structure/function relationships in OmpR and other winged-helix transcription factors. *Curr. Opin. Microbiol.* **5**:135–141.
17. Kobayashi, K., M. Ogura, H. Yamaguchi, K. Yoshida, N. Ogasawara, T. Tanaka, and Y. Fujita. 2001. Comprehensive DNA microarray analysis of *Bacillus subtilis* two-component regulatory systems. *J. Bacteriol.* **183**:7365–7370.
18. Kunst, F., N. Ogasawara, I. Moszer, A. M. Albertini, G. Alloni, V. Azevedo, M. G. Bertero, P. Bessieres, A. Bolotin, S. Borchert, R. Borriss, L. Boursier, A. Brans, M. Braun, S. C. Brignell, S. Bron, S. Brouillet, C. V. Bruschi, B. Caldwell, V. Capuano, N. M. Carter, S. K. Choi, J. J. Codani, I. F. Conner-ton, A. Danchin, et al. 1997. The complete genome sequence of the gram-positive bacterium *Bacillus subtilis*. *Nature* **390**:249–256.
19. Kuroda, M., H. Kuroda, T. Oshima, F. Takeuchi, H. Mori, and K. Hiramatsu. 2003. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in *Staphylococcus aureus*. *Mol. Microbiol.* **49**:807–821.
20. Lazar, K., and S. Walker. 2002. Substrate analogues to study cell-wall biosynthesis and its inhibition. *Curr. Opin. Chem. Biol.* **6**:786–793.
21. Marshall, C. G., I. A. Lessard, I. Park, and G. D. Wright. 1998. Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms. *Antimicrob. Agents Chemother.* **42**:2215–2220.
22. Mascher, T., N. G. Margulis, T. Wang, R. W. Ye, and J. D. Helmann. 2003. Cell wall stress responses in *Bacillus subtilis*: the regulatory network of the bacitracin stimulon. *Mol. Microbiol.* **50**:1591–1604.
23. Miller, J. H. 1972. *Experiments in molecular genetics*. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
24. Neu, T. R. 1996. Significance of bacterial surface-active compounds in interaction of bacteria with interfaces. *Microbiol. Rev.* **60**:151–166.
25. Neumüller, A. M., D. Konz, and M. A. Marahiel. 2001. The two-component regulatory system BacRS is associated with bacitracin “self-resistance” of *Bacillus licheniformis* ATCC 10716. *Eur. J. Biochem.* **268**:3180–3189.
26. Ohki, R., Giyanto, K. Tateno, W. Masuyama, S. Moriya, K. Kobayashi, and N. Ogasawara. 2003. The BceRS two-component regulatory system induces expression of the bacitracin transporter, BceAB, in *Bacillus subtilis*. *Mol. Microbiol.* **49**:1135–1144.
27. Pollock, T. J., L. Thorne, M. Yamazaki, M. J. Mikolajczak, and R. W. Armentrout. 1994. Mechanism of bacitracin resistance in gram-negative bacteria that synthesize exopolysaccharides. *J. Bacteriol.* **176**:6229–6237.
28. Rosamond, J., and A. Allsop. 2000. Harnessing the power of the genome in the search for new antibiotics. *Science* **287**:1973–1976.
29. Sardesai, Y., and S. Bhosle. 2002. Tolerance of bacteria to organic solvents. *Res. Microbiol.* **153**:263–268.
30. Slack, F. J., J. P. Mueller, and A. L. Sonenshein. 1993. Mutations that relieve nutritional repression of the *Bacillus subtilis* dipeptide permease operon. *J. Bacteriol.* **175**:4605–4614.
31. Tsuda, H., Y. Yamashita, Y. Shibata, Y. Nakano, and T. Koga. 2002. Genes involved in bacitracin resistance in *Streptococcus mutans*. *Antimicrob. Agents Chemother.* **46**:3756–3764.
32. Ulijasz, A. T., A. Grenader, and B. Weisblum. 1996. A vancomycin-inducible *lacZ* reporter system in *Bacillus subtilis*: induction by antibiotics that inhibit cell wall synthesis and by lysozyme. *J. Bacteriol.* **178**:6305–6309.
33. Vagner, V., E. Dervyn, and S. D. Ehrlich. 1998. A vector for systematic gene inactivation in *Bacillus subtilis*. *Microbiology* **144**:3097–3104.
34. Walsh, C. 2003. *Antibiotics: actions, origins, resistance*. ASM Press, Washington, D.C.
35. Walters, W. P., and M. Namchuk. 2003. Designing screens: how to make your hits a hit. *Nat. Rev. Drug Discov.* **2**:259–266.
36. Weiner, L., and P. Model. 1994. Role of an *Escherichia coli* stress-response operon in stationary-phase survival. *Proc. Natl. Acad. Sci. USA* **91**:2191–2195.
37. Zuber, P., and R. Losick. 1987. Role of AbrB in Spo0A- and Spo0B-dependent utilization of a sporulation promoter in *Bacillus subtilis*. *J. Bacteriol.* **169**:2223–2230.